CIGNA CORPORATION

(CI)
  Report
Delayed Nyse  -  05/16 03:48:36 pm EDT
266.24 USD   +2.72%
06:48aJPMorgan Raises Cigna to Overweight From Neutral, Price Target to $304 From $248
MT
05/11TRANSCRIPT : Cigna Corporation Presents at Bank of America 2022 Healthcare Conference, May-11-2022 10:40 AM
CI
05/10Raymond James Adjusts Cigna's Price Target to $300 From $275, Keeps Strong Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cigna Corporation : No turn-around in sight

01/20/2022 | 03:25am EDT
long trade
Stop-loss triggered
Entry price : 238.4$ | Target : 265$ | Stop-loss : 224$ | Potential : 11.16%
Cigna Corporation shares show a positive technical situation which suggests a continuation of the upward dynamic over the medium term.
Investors have an opportunity to buy the stock and target the $ 265.
Cigna Corporation : Cigna Corporation : No turn-around in sight
Summary
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 14.98 for the current year.
  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.

Weaknesses
  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

© MarketScreener.com 2022

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2022 179 B - -
Net income 2022 5 236 M - -
Net Debt 2022 25 696 M - -
P/E ratio 2022 15,4x
Yield 2022 1,65%
Capitalization 82 234 M 82 234 M -
EV / Sales 2022 0,60x
EV / Sales 2023 0,57x
Nbr of Employees 72 963
Free-Float 79,5%
Upcoming event on CIGNA CORPORATION
06/03/22Investor Day
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 259,19 $
Average target price 281,96 $
Spread / Average Target 8,78%
EPS Revisions
Managers and Directors
David Michael Cordani Chairman, President & Chief Executive Officer
Brian C. Evanko Chief Financial Officer & Executive Vice President
Noelle K. Eder Global Chief Information Officer & Executive VP
Paul Sanford Executive Vice President-Operations
William J. DeLaney Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CIGNA CORPORATION12.87%82 234
UNITEDHEALTH GROUP-3.33%455 388
ANTHEM, INC.4.94%117 276
HUMANA INC.-5.38%55 517
CENTENE CORPORATION-0.10%48 148
MOLINA HEALTHCARE, INC.-6.98%17 361